Toxicity associated with high-dose intravenous methotrexate for hematological malignancies

References

• Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010;2:293–301.
   PubMedGoogle Scholar
• Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol. 2009;27(2):61–70.
   PubMed Web of Science ®Google Scholar
• Leveque D, Santucci R, Gourieux B, et al. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol. 2011;4(6):743–750.
   PubMedGoogle Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Pampin R, Labeaga Y, Rodriguez B, et al. Experience with ambulatory high-dose methotrexate administration as CNS prophylaxis in patients with non-Hodgkin lymphoma. J Oncol Pharm Pract. 2020;26(3):549–555.
   PubMed Web of Science ®Google Scholar
• Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther. 1978;23(1):68–72.
   PubMed Web of Science ®Google Scholar
• Wiczer T, Dotson E, Tuten A, et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430–436.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Park H, Lee JS, et al. Methotrexate elimination and toxicity: MTHFR 677C > T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate. Hematol Oncol. 2017;35(4):504–509.
   PubMed Web of Science ®Google Scholar
• Reiss SN, Buie LW, Adel N, et al. Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol. 2016;95(12):2009–2015.
   PubMed Web of Science ®Google Scholar
• Chang X, Guo Y, Su L, et al. Influence of MTHFR C677T polymorphism on high-dose methotrexate-related toxicity in patients with primary central nervous system diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(2):91–96.
   PubMed Web of Science ®Google Scholar
• Mullikin D, Ranch D, Khalfe Y, et al. Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leuk Lymphoma. 2020;61(11):2771–2774.
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–215.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28(25):3979–3986.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Borner K, Muller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist. 2007;12(11):1299–1308.
   PubMed Web of Science ®Google Scholar
• Puckrin R, Darsa H, Ghosh S, et al. Lack of effectiveness of intravenous high-dose methotrexate for prevention of CNS relapse in patients with high-risk DLBCL: a retrospective analysis from Alberta, Canada. Blood. 2020;136(Supplement 1):26–27.
   Google Scholar
• Abramson JS, Hellmann M, Barnes JA, et al. Intravenous methotrexate as Central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–4290.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients. Blood. 2022;139(16):2499–2511.
   PubMed Web of Science ®Google Scholar
• Lewis KL, Jakobsen LH, Villa D High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. 905. Outcomes Research-Lymphoid Malignancies: Lymphoma/CLL Real-World Data. American Society of Hematology 62nd annual meeting and exposition; 12/11/2021; Atlanta, Georgia, et al. 2021.
   Google Scholar
• Reed DR, Pierce EJ, Sen JM, et al. A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate. Cancer Manag Res. 2019;11:8065–8072.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-27–e227.
   PubMed Web of Science ®Google Scholar
• McMillan AK, Phillips EH, Kirkwood AA, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Ann Oncol. 2020;31(9):1251–1259.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–1520.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–1049.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kuker W, Uhl M, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57(6):843–847.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188–195.
   PubMed Web of Science ®Google Scholar
• Wight JC, Yue M, Keane C, et al. Outcomes of synchronous systemic and Central Nervous System (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. Br J Haematol. 2019;187(2):174–184.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhu X, Li W, et al. Influence of methylenetetrahydrofolate reductase C677T and A1298C polymorphism on high-dose methotrexate-related toxicities in pediatric non-Hodgkin lymphoma patients. Front Oncol. 2021;11:598226.
   PubMed Web of Science ®Google Scholar